

## I. AMENDMENTS

In the claims:

Sub c<sup>2</sup> <sup>amended</sup>

1. A method for treating intracellular infections with warm-blooded animals, comprising:

(a) administering to a warm-blooded animal a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen derived from an intracellular pathogen; and

(b) administering to said warm-blooded animal a protein which comprises said immunogenic portion of said antigen, such that an immune response is generated.

B<sup>1</sup>

3. (Amended) The method according to claim 1, wherein said protein is administered prior to administration of said gene delivery vehicle.

B<sup>2</sup> 3

5. (Amended) The method according to claim 3, wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus (FIV), and human immunodeficiency virus (HIV).

11. (Amended) The method according to claim 1, wherein said gene delivery vehicle is a recombinant retrovirus.

B<sup>4</sup>

12. (Amended) The method according to claim 1, wherein said gene delivery vehicle is selected from the group consisting of alphaviruses, adeno-associated virus and parvovirus.

13. (Amended) The method according to claim 1, wherein said gene delivery

vehicle is a nucleic acid expression vector, or a eukaryotic layered vector initiation system.

B 4  
14. (Amended) A composition comprising a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen derived from an intracellular pathogen, a protein which comprises said immunogenic portion of said antigen, and a pharmaceutically acceptable carrier or diluent.

B 5  
17. (Amended) The composition according to claim 16, wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus (FIV), and human immunodeficiency virus (HIV).

B 6  
21. (Amended) The composition according to claim 20, wherein said hepatitis C antigen is selected from the group consisting of core antigen C, E1, E2/NS1, NS2, NS3, NS4 and NS5.

B 7  
23. (Amended) The composition according to claim 1, wherein said gene delivery vehicle is a recombinant retrovirus.

B 8  
24. (New) The method of claim 1, wherein the gene delivery vehicle comprises naked DNA.

sub C 4  
25. (New) The composition of claim 1, wherein the gene delivery vehicle comprises naked DNA.